Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Blood Advances|July 28, 2025
Targeting S100A9-mediated inflammation: A novel therapeutic approach for CLLAngimar Uriepero-Palma, Maria Elena Marquez, Eugenia Payque, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Transplantation and Cellular Therapy|May 17, 2022
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for LymphomaAnna Barata, Aasha I Hoogland, Anuhya Kommalapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Blood Advances|July 28, 2025
Targeting S100A9-mediated inflammation: A novel therapeutic approach for CLLAngimar Uriepero-Palma, Maria Elena Marquez, Eugenia Payque, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Transplantation and Cellular Therapy|May 17, 2022
Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for LymphomaAnna Barata, Aasha I Hoogland, Anuhya Kommalapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Pageof 14